My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.

    Andersen MH, Soerensen RB, Becker JC, thor Straten P.

    J Transl Med. 2006 Sep 4;4:38.PMID: 16948867 [PubMed]Related articlesFree article

    2.

    Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.

    Kobayashi J, Torigoe T, Hirohashi Y, Idenoue S, Miyazaki A, Yamaguchi A, Hiratsuka H, Sato N.

    J Transl Med. 2009 Jan 6;7:1.PMID: 19123955 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.

    Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N.

    Clin Cancer Res. 2002 Jun;8(6):1731-9.PMID: 12060610 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.

    Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K.

    J Transl Med. 2004 Jun 13;2(1):19.PMID: 15193151 [PubMed - as supplied by publisher]Related articlesFree article

    5.

    [Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy]

    Tsuruma T, Torigoe T, Hata F, Furuhata T, Sato N, Hirata K.

    Gan To Kagaku Ryoho. 2004 Oct;31(11):1634-6. Japanese. PMID: 15553667 [PubMed - indexed for MEDLINE]Related articles

    6.

    Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.

    Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K.

    Lung Cancer. 2005 May;48(2):281-9. Epub 2004 Dec 22.PMID: 15829330 [PubMed - indexed for MEDLINE]Related articles

    7.

    Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.

    Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC.

    Cancer Immunol Immunother. 2006 Oct;55(10):1294-8. Epub 2005 Nov 29.PMID: 16315030 [PubMed - indexed for MEDLINE]Related articles

    8.

    HLA-B35-restricted immune responses against survivin in cancer patients.

    Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH.

    Int J Cancer. 2004 Mar 1;108(6):937-41.PMID: 14712500 [PubMed - indexed for MEDLINE]Related articles

    9.

    Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.

    Karanikas V, Soukou F, Kalala F, Kerenidi T, Grammoustianou ES, Gourgoulianis KI, Germenis AE.

    Clin Immunol. 2008 Nov;129(2):230-40. Epub 2008 Sep 13.PMID: 18789878 [PubMed - indexed for MEDLINE]Related articles

    10.

    A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

    Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N.

    Clin Cancer Res. 2005 Feb 15;11(4):1474-82.PMID: 15746049 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.

    Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, Yagihashi A, Hirohashi Y, Asanuma H, Shimozawa K, Okazaki M, Mizushima Y, Nomura N, Sato N, Hirata K.

    J Transl Med. 2008 May 10;6:24.PMID: 18471305 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.

    Shimato S, Natsume A, Wakabayashi T, Tsujimura K, Nakahara N, Ishii J, Ito M, Akatsuka Y, Kuzushima K, Yoshida J.

    J Neurosurg. 2008 Jul;109(1):117-22.PMID: 18590440 [PubMed - indexed for MEDLINE]Related articles

    13.

    Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.

    Jin M, Komohara Y, Shichijo S, Harada M, Yamanaka R, Miyamoto S, Nikawa J, Itoh K, Yamada A.

    Oncol Rep. 2008 May;19(5):1277-83.PMID: 18425388 [PubMed - indexed for MEDLINE]Related articles

    14.

    Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.

    Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, Hirohashi Y, Masumori N, Tsukamoto T, Sato N.

    Cancer Immunol Immunother. 2009 Nov;58(11):1801-7. Epub 2009 Mar 18.PMID: 19294381 [PubMed - indexed for MEDLINE]Related articles

    15.

    Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.

    Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trümper L, Schroers R.

    Hum Immunol. 2007 Jul;68(7):572-6. Epub 2007 Apr 11.PMID: 17584578 [PubMed - indexed for MEDLINE]Related articles

    16.

    Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.

    Morishima S, Akatsuka Y, Nawa A, Kondo E, Kiyono T, Torikai H, Nakanishi T, Ito Y, Tsujimura K, Iwata K, Ito K, Kodera Y, Morishima Y, Kuzushima K, Takahashi T.

    Int J Cancer. 2007 Feb 1;120(3):594-604.PMID: 17096336 [PubMed - indexed for MEDLINE]Related articles

    17.

    Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.

    Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, Ito N, Hasegawa T, Tsukamoto T, Sato N.

    Clin Cancer Res. 2008 Nov 1;14(21):6916-23.PMID: 18980986 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.

    Hofmann UB, Voigt H, Andersen MH, Straten PT, Becker JC, Eggert AO.

    Eur J Immunol. 2009 May;39(5):1419-24.PMID: 19337999 [PubMed - indexed for MEDLINE]Related articles

    19.

    HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.

    Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP, Yang SM.

    Neoplasia. 2008 Sep;10(9):977-86.PMID: 18714399 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.

    Wang Y, Takao Y, Harada M, Komatsu N, Ono T, Sata M, Itoh K, Yamada A.

    Cell Immunol. 2006 May;241(1):38-46. Epub 2006 Sep 11.PMID: 16963008 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk